<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04300998</url>
  </required_header>
  <id_info>
    <org_study_id>19-452</org_study_id>
    <nct_id>NCT04300998</nct_id>
  </id_info>
  <brief_title>Study of CAR-T Therapy in Older Patients</brief_title>
  <official_title>A Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluations for Older Lymphoma Patients Receiving CART Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out how older patients respond to CAR-T cell therapy and how
      the treatment affects their quality of life. This is a quality of life study and
      participating in the study does not involve receiving any treatment, other than the standard
      treatment for participants' disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">March 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who complete all required assessment visits prior to disease progression or death</measure>
    <time_frame>1 year</time_frame>
    <description>Participants who complete all assessment visits prior to disease progression or death will be considered as a success for a feasibility endpoint.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Lymphoma</condition>
  <condition>Refractory B-Cell Lymphoma</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>DLBCL NOS</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <description>Participants are undergoing CART therapy for relapsed refractory high-grade B-cell lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Activities of Daily Living/ADLs</intervention_name>
    <description>7 activities: bathing, dressing, grooming, feeding, walking inside the home, walking outside the home, and bladder and bowel control. Participants get 2 points for each activity that is not limited at all, 1 point for limited a little, and 0 points for limited a lot. Total ADL score ranges from 0 to 14</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <other_name>ADLs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Instrumental Activity of Daily Living</intervention_name>
    <description>8 activities: telephone use, doing laundry, shopping, preparing meals, doing housework, handling own medications, handling money and finances, and transportation to visit one's doctor. Participants get 2 points for each activity that can be done without help, 1 point for needing some help, and 0 point for being unable to do. Total iADL score ranges from 0 to16.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <other_name>iADLS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Timed Up and Go</intervention_name>
    <description>Participants are asked to get up from the chair, walk 10 feet, turn, and walk back to the char (&lt;10 seconds, 10-20 seconds, &gt;20 seconds)</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognition</intervention_name>
    <description>Mini-Cognition test: CDT and 3-word recall</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Geriatric Depression Scale</intervention_name>
    <description>Four yes/no questions regarding patient's psychological status. Score ranges from 0 to 4, and a score of &gt;/=1 is usually indicative of depression.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Social Support</intervention_name>
    <description>Four 5-point Likert scale questions addressing 4 domains of social support: emotional/ informational, tangible, affectionate, and positive social interaction. Score for each item ranges from 1 to 5, and total score ranges from 4 to 20. A higher score means better social support.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Test of Attention</intervention_name>
    <description>assess selective auditory attention.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <other_name>BTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Trail Making Test</intervention_name>
    <description>Assesses visual scanning, graphomotor speed, and set shifting.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Controlled Oral Word Association Test</intervention_name>
    <description>A timed test of verbal fluency</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <other_name>COWAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hopkins Verbal Learning Test-Revised</intervention_name>
    <description>The HVLT-R is a test of verbal learning and recall. Scores obtained are the total number of words: 1) recalled over three trials; 2)recalled after a delay; 3) correctly recognized.</description>
    <arm_group_label>B-cell lymphoma</arm_group_label>
    <other_name>HVLT-R</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from all lymphoma specialists and all transplant physicians at
        the Memorial Sloan Kettering Cancer Center, including affiliated satellite sites. Patients
        are recruited without consideration of gender, country of origin, educational level, or
        income. There will be no reimbursement or payment toward the participation of this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are â‰¥60 years old

          -  have pathologically confirmed, relapsed refractory large B-cell lymphoma including
             DLBCL (de novo disease or transformed follicular lymphoma), DLBCL NOS, high grade
             B-cell lymphoma, and primary mediastinum B-cell lymphoma

          -  have progressed through two or more lines of therapy

          -  have Eastern Cooperative Group (ECOG) performance status of 0 to 2

          -  have no evidence of central nervous system disease at study entry

          -  meet cardiac, pulmonary, hepatic, and renal requirement for CART therapy as described
             in corresponding product package insert

          -  able to speak and understand English

        Exclusion Criteria:

          -  Prior CART therapy

          -  Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression,
             bipolar disorder, or schizophrenia, as per medical records or patient report

          -  History of a neurological disorder, neurodegenerative disease, or traumatic brain
             injury with loss of consciousness (&gt;60 minutes), as per medical records or patient
             report

          -  Current ongoing substance abuse and/or history of substance abuse, as per medical
             records or patient report
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Lin, MD, PhD</last_name>
    <phone>646-608-2646</phone>
    <email>linr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sergio Giralt, MD</last_name>
    <phone>646-608-3731</phone>
    <email>GiraltS@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Lin, MD, PhD</last_name>
      <phone>646-608-2646</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>March 6, 2020</last_update_submitted>
  <last_update_submitted_qc>March 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>CART therapy</keyword>
  <keyword>relapsed refractory large B-cell lymphoma</keyword>
  <keyword>High-grade B-cell Lymphoma</keyword>
  <keyword>DLBCL NOS</keyword>
  <keyword>Refractory B-Cell Lymphoma</keyword>
  <keyword>19-452</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

